Somnair Secures $4.3M Funding for Innovative Sleep Apnea Device Development

Somnair, a Towson, Md.-based startup founded by Johns Hopkins alumni, has successfully raised $4.3 million in seed funding to advance the development of its innovative device aimed at managing obstructive sleep apnea (OSA). This funding round, as detailed in an SEC filing, marks a significant step forward for the company, though the investors involved were not disclosed. The co-founders, all graduates of the Johns Hopkins Whiting School of Engineering's Biodesign program, bring a diverse set of skills and experiences to the venture, with CEO Anders Sideris highlighting the collaborative effort to address a critical gap in OSA treatment options.

The device developed by Somnair represents a novel approach to treating OSA, focusing on non-invasive neurostimulation to target the root cause of the condition. Unlike traditional CPAP machines, which many patients find uncomfortable and costly, Somnair's device is designed to be worn in the mouth like a retainer, applying gentle stimulation to a specific nerve that aids in opening the airway. This innovation stems from extensive research and observation by the co-founders, who spent over 1,000 hours engaging with physicians and patients to understand the challenges faced by those with OSA.

Early support from MedStar Health, following Somnair's presentation at Towson University's 2024 StarTUp Accelerator, underscores the potential impact of this technology. With an estimated 54 million Americans suffering from OSA, the condition not only affects sleep quality but also increases the risk of chronic diseases such as heart disease and diabetes. The team's ongoing proof-of-concept study with Johns Hopkins School of Medicine physicians has shown promising results, with early data from 22 patients supporting the device's efficacy in opening airways for those who cannot tolerate CPAP treatment.

The development of Somnair's device addresses a pressing need in the healthcare sector, offering hope for millions of OSA patients seeking alternative treatments. The successful seed funding round enables the company to continue its research and development efforts, bringing it closer to making a tangible difference in the lives of those affected by this debilitating condition.